Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a TP53- and BAX-Dependent Manner
Open Access
- 7 July 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (17) , 4910-4922
Abstract
Purpose: Bcl-2 has been effectively targeted in lymphoid malignancies. However, resistance is inevitable, and novel approaches to target mitochondrial apoptosis are necessary. AZD5991, a selective BH3-mimetic in clinical trials, inhibits Mcl-1 with high potency. Experimental Design: We explored the preclinical activity of AZD5991 in diffuse large B-cell lymphoma (DLBCL) and ibrutinib-resistant mantle cell lymphoma (MCL) cell lines, MCL patient samples, and mice bearing DLBCL and MCL xenografts using flow cytometry, immunoblotting, and Seahorse respirometry assay. Cas9 gene editing and ex vivo functional drug screen assays helped identify mechanisms of resistance to Mcl-1 inhibition. Results: Mcl-1 was expressed in DLBCL and MCL cell lines and primary tumors. Treatment with AZD5991 restricted growth of DLBCL cells independent of cell of origin and overcame ibrutinib resistance in MCL cells. Mcl-1 inhibition led to mitochondrial dysfunction as manifested by mitochondrial membrane depolarization, decreased mitochondrial mass, and induction of mitophagy. This was accompanied by impairment of oxidative phosphorylation. TP53 and BAX were essential for sensitivity to Mcl-1, and oxidative phosphorylation was implicated in resistance to Mcl-1 inhibition. Induction of prosurvival proteins (e.g., Bcl-xL) in stromal conditions that mimic the tumor microenvironment rendered protection of primary MCL cells from Mcl-1 inhibition, while BH3-mimetics targeting Bcl-2/xL sensitized lymphoid cells to AZD5991. Treatment with AZD5991 reduced tumor growth in murine lymphoma models and prolonged survival of MCL PDX mice. Conclusions: Selective targeting Mcl-1 is a promising therapeutic approach in lymphoid malignancies. TP53 apoptotic network and metabolic reprogramming underlie susceptibility to Mcl-1 inhibition.Keywords
All Related Versions
Funding Information
- Leukemia and Lymphoma Society (#2319–19)
- American Society of Hematology (1R01CA244576–01A1)
This publication has 50 references indexed in Scilit:
- Metabolic Signatures Uncover Distinct Targets in Molecular Subsets of Diffuse Large B Cell LymphomaCancer Cell, 2012
- Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respirationNature Cell Biology, 2012
- Glucose-Independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B CellsCell Metabolism, 2012
- Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in miceBlood, 2011
- Choosing between glycolysis and oxidative phosphorylation: A tumor's dilemma?Biochimica et Biophysica Acta (BBA) - Bioenergetics, 2011
- Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicityProceedings of the National Academy of Sciences of the United States of America, 2010
- The landscape of somatic copy-number alteration across human cancersNature, 2010
- Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximabBlood, 2009
- Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIMOncogene, 2004
- Expression of Mcl‐1 in mantle cell lymphoma is associated with high‐grade morphology, a high proliferative state, and p53 overexpressionThe Journal of Pathology, 2002